News

New Management for Roche Diagnostics GmbH

Roche Diagnostics GmbH announces a change in management effective January 1, 2020. Dr. Ursula Redeker is stepping down from her position as Spokesperson of the Management Board of Roche Diagnostics GmbH. Claus Haberda becomes the new Managing Director of RDG and thus also a member of the Management Board of Roche Deutschland Holding GmbH.

Claus Haberda

Claus Haberda studied food technology at the TU München-Weihenstephan. In 1992, the Kassel-born (56) joined Roche in Penzberg, then still Boehringer Mannheim. He began his career in the company as head of production planning and production controlling for the biotechnology sector. Later, Haberda was Global Head of Finance for the Roche Applied Science business unit and then Head of Global Production for Centralised and Point of Care Solutions from Mannheim. In 2009 he was appointed Head of the Penzberg facility.

Since 1 March 2017, Haberda has been Head of Finance and Controlling at Roche Diagnostics GmbH, based in Penzberg and Mannheim. He also retains this role as Managing Director of Roche Diagnostics GmbH. “I am looking forward to the new tasks and would like to work on further strengthening the role of the German sites in Roche’s global network,” says Haberda, adding: “Our strengths – outstanding employees, creativity and diversity of tasks and competencies – are our success factors.”

Ursula Redeker will return to Basel and assume global responsibility for strategic projects. She looks back on six eventful years. During this time Roche has been driving developments such as the cobas® Plasma Separation Card. The card makes it easy to store and transport blood samples for HIV diagnosis in developing countries. The company also introduced new products to the market. These include the next generation of Elecsys® immunodiagnostic tests. These have been a blockbuster in the company’s diagnostic portfolio for over 20 years.

Redeker also supported the expansion of the two sites in Mannheim and Penzberg. During this period Roche invested around 2 billion euros to strengthen the competence of its sites. Redeker played a key role in shaping Roche Diagnostics GmbH and successfully advanced its digital transformation. In doing so, it always turned its attention to the outside world. Redeker was committed to positioning Roche as a partner for science and research in the Rhine-Neckar metropolitan region and the Munich area. Claus Haberda most recently worked for Roche as Head of Finance and Controlling in Penzberg and Mannheim.